Post-marketing safety evaluation of mirogabalin using the JADER database
BackgroundMirogabalin, a novel third-generation α2-δ calcium channel ligand, is approved for diabetic peripheral neuropathic pain (DPNP). However, its post-marketing safety profile remains insufficiently characterized, particularly regarding novel signals and comparative safety profiles with establi...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Frontiers Media S.A.
2026-06-01
|
| Sraith: | Frontiers in Pharmacology |
| Ábhair: | |
| Rochtain ar líne: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1833433/full |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|